Document is current
Any future updates will be listed below
-
Authors
Ossenkoppele, Rik https://orcid.org/0000-0003-1584-7477
Pichet Binette, Alexa https://orcid.org/0000-0001-5218-3337
Groot, Colin
Smith, Ruben https://orcid.org/0000-0001-7147-0112
Strandberg, Olof
Palmqvist, Sebastian https://orcid.org/0000-0002-9267-1930
Stomrud, Erik
Tideman, Pontus
Ohlsson, Tomas
Jögi, Jonas
Johnson, Keith
Sperling, Reisa
Dore, Vincent https://orcid.org/0000-0002-8051-0558
Masters, Colin L.
Rowe, Christopher
Visser, Denise
van Berckel, Bart N. M. https://orcid.org/0000-0002-5299-3628
van der Flier, Wiesje M. https://orcid.org/0000-0001-8766-6224
Baker, Suzanne
Jagust, William J. https://orcid.org/0000-0002-4458-113X
Wiste, Heather J.
Petersen, Ronald C. https://orcid.org/0000-0002-8178-6601
Jack, Clifford R. Jr https://orcid.org/0000-0001-7916-622X
Hansson, Oskar https://orcid.org/0000-0001-8467-7286
- License Information
-
More Information
Article History
Received: 18 May 2022
Accepted: 21 September 2022
First Online: 10 November 2022
Competing interests
: O.H. has acquired research support (for the institution) from ADx, AVID Radiopharmaceuticals, Biogen, Eli Lilly, Eisai, Fujirebio, GE Healthcare, Pfizer and Roche. In the past 2 years, he received consultancy/speaker fees from AC Immune, Amylyx Pharmaceuticals, ALZpath, BioArctic, Biogen, Cerveau Technologies, Fujirebio, Genentech, Novartis, Roche and Siemens. R.O. gave a lecture in a symposium sponsored by GE Healthcare (fee paid to the institution). S.P. has served on scientific advisory boards and/or given lectures in symposia sponsored by Biogen, Eli Lilly, Geras Solutions and Roche. W.J.J. consults for Eli Lilly, Eisai, Bioclinica and Prothena. C.R. is a scientific advisor to Cerveau Technologies, Prothena, Roche and has received research grants (paid to the institution) from Biogen, Eisai and Cerveau Technologies. R.C.P. has consulted for Roche, Merck, Biogen, Eisai, Genentech and Nestle and receives research funding from the National Institutes of Health (NIH). W.F. has performed contract research for Biogen and Boehringer Ingelheim, has been an invited speaker at Boehringer Ingelheim, Biogen, Danone, Eisai, WebMD Neurology (Medscape) and Springer Healthcare, is consultant to the Oxford Health Policy Forum CIC, Roche and Biogen, participated in the advisory boards of Biogen and Roche and is a member of the steering committee of PAVE and Think Brain Health (all funding/fees were paid to the institution). C.R.J. serves on an independent data monitoring board for Roche, has served as a speaker for Eisai and consulted for Biogen but receives no personal compensation from any commercial entity. C.R.J. receives research support from the NIH and the Alexander Family Alzheimer’s Disease Research Professorship of the Mayo Clinic. The other authors declare no competing interests.
